On treatment prediction of post-treatment sustained response to Peginterferon alfa-2a for HBeAg-negative Chronic Hepatitis B (CHB) patients using HBsAg and HBV DNA levels at weeks 12 and 24: PERSEAS cohort final results

被引：0

作者：

Goulis, Ioannis ^{[1
]}

Karatapanis, Stylianos ^{[2
]}

Akriviadis, Evangelos A. ^{[1
]}

Deutsch, Melanie ^{[3
]}

Dalekos, George N. ^{[4
,5
]}

Raptopoulou-Gigi, Maria ^{[3
]}

Mimidis, Konstantinos ^{[6
]}

Germanidis, Georgios ^{[7
]}

Triantos, Christos K. ^{[8
]}

Drakoulis, Christos ^{[9
]}

Chounta, Athina ^{[10
]}

Vafiadis, Irene ^{[11
]}

Hatzis, Grigorios ^{[12
]}

Gagalis, Asterios ^{[13
]}

Vlachogiannakos, Jiannis ^{[11
]}

Zintzaras, Elias ^{[14
,15
]}

Koulouris, Sokratis ^{[16
]}

Bakalos, George ^{[14
,16
]}

Papatheodoridis, George V. ^{[3
]}

机构：

[1] Hippokrateion Hosp, Dept Internal Med 4, Thessaloniki, Greece

[2] Rhodes Hosp, Dept Internal Med 1, Rhodes, Greece

[3] Hippokrateion Hosp, Dept Internal Med 2, Athens, Greece

[4] Univ Thessaly, Sch Med, Dept Med, Larisa, Greece

[5] Univ Thessaly, Res Lab Internal Med, Larisa, Greece

[6] Democritus Univ Thrace, Sch Med, Dept Internal Med 1, Alexandroupolis, Greece

[7] AHEPA Hosp, Dept Gastroenterol, Internal Med Clin 1, Thessaloniki, Greece

[8] Univ Patras, Sch Med, Dept Gastroenterol, Patras, Greece

[9] Nikaia Hosp, Dept Internal Med 2, Athens, Greece

[10] Univ Hosp ATTIKON, Dept Internal Med, Athens, Greece

[11] Laiko Univ, Gen Hosp, Dept Internal Med Propaedeut, Athens, Greece

[12] Laikon Gen Hosp, Physiopathol Dept, Athens, Greece

[13] Papageorgiou Gen Hosp, Dept Gastroenterol, Thessaloniki, Greece

[14] Univ Thessaly, Sch Med, Dept Biomath, Larisa, Greece

[15] Tufts Univ, Sch Med, Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA

[16] Roche Hellas, Med Affairs, Athens, Greece

来源：

HEPATOLOGY | 2013年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1015

引用

页码：697A / 698A

页数：2

共 50 条

[41] END OF TREATMENT INTRAHEPATIC HEPATITIS B (HBV) COVALENTLY CLOSED CIRCULAR DNA (CCCDNA) PREDICTS SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR
Takkenberg, Bart
Zaaijer, Hans L.
de Niet, Annikki
Weegink, Christine J.
Terpstra, Valeska
Koot, Maarten
Dijkgraaf, Marcel
Beld, Marcel
Reesink, Hendrik W.
HEPATOLOGY, 2009, 50 (04) : 535A - 536A
[42] PEGBELIVER STUDY: HBSAG DECLINE AT WEEK 24 OF EXTENDED PEGINTERFERON ALFA-2A (PEG-IFNα-2A) THERAPY IS SIGNIFICANTLY ASSOCIATED WITH POST-TREATMENT RESPONSE IN HBEAG-NEGATIVE GENOTYPE D PATIENTS
Lampertico, P.
Vigano, M.
Lanza, A. Galeota
Sagnelli, E.
Fasano, M.
Di Marco, V.
Bininsegna, S.
Farci, P.
Fargion, S.
Giuberti, T.
Iannacone, C.
Massetto, B.
Martins, E. B.
Colombo, M.
JOURNAL OF HEPATOLOGY, 2011, 54 : S293 - S293
[43] TREATMENT WITH CLEVUDINE FOR 24 WEEKS RESULTS IN SUSTAINED ANTIVIRAL RESPONSE ASSOCIATED WITH CONTINUED HBsAg DECREASE 24 WEEKS POST-TREATMENT IN HBeAg-POSITIVE PATIENTS
Kim, J. H.
Yoo, B. C.
Yeon, J. E.
Kim, B. I.
Jeon, W. K.
Kim, H. S.
Lee, C. H.
Lee, J. W.
Kang, H. S.
Lee, S. U.
Lee, S.
Park, H.
Kim, D. Y.
Lee, K. S.
Kim, B. H.
Kwon, S. Y.
Kim, Yun Soo
Lee, H. I.
Yang, J. M.
Kim, Young Seok
Lee, H. S.
JOURNAL OF HEPATOLOGY, 2009, 50 : S383 - S383
[44] BASELINE HBSAG AS PREDICTOR FOR HBSAG SEROCONVERSION IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR: FINAL RESULTS OF A PROSPECTIVE OPEN LABEL STUDY
Takkenberg, Bart
de Niet, Annikki
Zaaijer, Hans L.
Weegink, Christine J.
Terpstra, Valeska
Dijkgraaf, Marcel
Jansen, Peter L.
Rijckborst, Vincent
Janssen, Harry L.
Beld, Marcel
Reesink, Hendrik W.
HEPATOLOGY, 2011, 54 : 1039A - 1040A
[45] Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy for HBEAG-negative chronic hepatitis B
Marcellin, P
Bonino, F
Lau, GY
Farci, P
Yurdaydin, C
Piratvisuth, T
Jin, R
Gurel, S
Hadziyannis, S
Lu, ZM
Popescu, M
HEPATOLOGY, 2005, 42 (04) : 580A - 580A
[46] A real-world experience in baseline predictors of virological response to Peginterferon Alfa-2a in patients with HBeAg-negative chronic hepatitis B
Chen, Yi-Cheng
Jeng, Rachel Wen-Juei
Hsu, Chao-Wei
Lin, Chun-Yen
Sheen, I-Shyan
Chien, Rong-Nan
Liaw, Yun-Fan
HEPATOLOGY, 2016, 64 : 927A - 927A
[47] HIGH LEVELS OF HBSAG AND HBV DNA DURING TREATMENT PREDICT FAILURE FOR HBEAG SEROCONVERSION IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS
Takkenberg, Bart
Zaaijer, Hans L.
de Niet, Annikki
Weegink, Christine J.
Terpstra, Valeska
Koot, Maarten
Dijkgraaf, Marcel
Jansen, Peter L.
Janssen, Harry L.
Beld, Marcel
Reesink, Hendrik W.
HEPATOLOGY, 2009, 50 (04) : 541A - 541A
[48] 48 WEEKS OF PEGINTERFERON ALFA-2A ALONE OR IN COMBINATION WITH RIBAVIRIN FOR HBEAG-NEGATIVE CHRONIC HEPATITIS B: ADDITION OF RIBAVIRIN DOES NOT IMPROVE RESPONSE RATES
Janssen, Harry L.
Rijckborst, Vincent
Cakaloglu, Yilmaz
Ferenci, Peter
Tabak, Fehmi
Akdogan, Meral
Simon, Krzysztof
Raptopoulou-Gigi, Maria
Oermeci, Necati
Zondervan, Pieter E.
Verhey, Elke
van Vuuren, Anneke J.
ter Borg, Martijn J.
Hansen, Bettina E.
HEPATOLOGY, 2008, 48 (04) : 752A - 752A
[49] Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naive patients with genotype 1, chronic hepatitis C
Neumann, Avidan U.
Pianko, Stephen
Zeuzem, Stefan
Yoshida, Eric M.
Benhamou, Yves
Mishan, Moshe
McHutchison, John G.
Pulkstenis, Erik
Subramanian, G. Mani
JOURNAL OF HEPATOLOGY, 2009, 51 (01) : 21 - 28
[50] On-treatment predictors of sustained biochemical and virological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon α-2a (40 kDa) (Pegasys®)
Farci, P
Marcellin, P
Lu, ZM
Diago, M
Lai, MY
Gurel, S
Kittis, G
Yurdaydin, C
Zahm, F
Bonino, F
JOURNAL OF HEPATOLOGY, 2005, 42 : 175 - 175

← 1 2 3 4 5 →